Alison Church

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials

Marc Decramer, Antonio Anzueto, Edward Kerwin et al. · The Lancet Respiratory Medicine · 2014 · 231 citations

Asthma, Umeclidinium Monotherapies, Advanced Lung Disease +6

Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD

Bartolomé R. Celli, Glenn Crater, Sally Kilbride et al. · CHEST Journal · 2014 · 155 citations

Umeclidinium/vilanterol 125/25, Pulmonary Care, Advanced Lung Disease +5

Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial

M. Reza Maleki-Yazdi, Thomas Kaelin, Nathalie Richard et al. · Respiratory Medicine · 2014 · 117 citations · Full text

Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study

James F. Donohue, Dennis E. Niewoehner, Jean Brooks et al. · Respiratory Research · 2014 · 92 citations · Full text

Umeclidinium in patients with COPD: a randomised, placebo-controlled study

Roopa Trivedi, Nathalie Richard, Rashmi Mehta et al. · European Respiratory Journal · 2013 · 91 citations · Full text